The global downstream processing market size was valued at USD 22.0 Billion in 2021 and it is expected to enjoy a valuation of USD 24.9 Billion by the end of 2022, Furthermore, with rising adoption across biopharmaceutical companies and contract research organizations, the overall demand for downstream processing products is projected to increase at a CAGR of 11.3% between 2022 and 2032, totaling a market valuation of USD72.3 Billion by the year 2032.
Based on product, the chromatography columns and resins segment held around 37.9% share in the global downstream processing market in 2021 and it is likely to retain its dominance even during the projected period (2022 to 2032).
| Attribute | Key Insights |
|---|---|
| Downstream Processing Market Base Value (2021) | USD 22.0 Billion |
| Estimated Market Value (2022) | USD 24.9 Billion |
| Projected Market Value (2032) | USD 72.3 Billion |
| CAGR 2022 to 2032 | 11.3% |
| Market Share of Top 5 Countries | 55.3% |
The manufacturing of pharmaceuticals, food, beverages, and nutraceutical in the present world is largely supported by industrial-scale bioprocessing. The economies of scale and scope that are so heavily reliant on titers, productivity, and product yields are progressively used by these manufacturing processes to increase their profitability.
With a surge in demand for therapeutics, end users like biopharmaceutical companies and contract research organizations are incorporating downstream processing techniques for the development and manufacture of bulk vaccines and other pharmaceutical products.
Government support through research incubators has provided a boost to the development of downstream processing technologies. This has provided a boost to the biopharmaceutical industry’s growth globally which in turn will continue to play a crucial role in expanding the overall downstream processing market size.
Downstream processing is used to manufacture products like antibiotics, vaccines, antibodies, industrial enzymes, and hormones such as insulin. Rising production and consumption of these products due to rising incidences of infectious and chronic diseases like hepatitis, diabetes, dengue, swine flu, etc., will therefore continue to boost the growth of the downstream processing market during the forecast period.
The overall downstream processing market formed approximately 2.2% of the global biotechnology market which stood at USD 1,023.9 Billion in 2021.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of downstream processing products are projected to grow at 11.3% CAGR between 2022 and 2032, in comparison to the 5.8% CAGR registered during the historical period from 2012 to 2021.
Rising usage of downstream processing techniques for manufacturing various biopharmaceutical products and increasing investments in research and development by pharmaceutical and biopharmaceutical companies are some of the key factors driving the global downstream processing market
Similarly, Rising government funding for basic and clinical research to address real clinical needs, burgeoning demand for biopharmaceuticals, and growing adoption of automation across the pharmaceutical industry is expected to boost the sales of some of the key downstream processing products during the forecast period.
In recent years, biopharmaceutical companies and contract research organizations have ramped up their production of proteins, vaccines, antibodies, and other biopharmaceutical products by employing upstream processes and downstream processing techniques.
The retrieval and purification of biosynthetic products from natural sources, such as plant or animal tissue, is referred to as downstream processing. For example, a crucial step in the production of antibiotics like penicillin is downstream processing.
The method includes separating and purifying antibiotics from a variety of media. Due to the rising need for biologics, downstream technology is increasingly being used in industrial-scale and laboratory applications. This trend is expected to boost downstream processing market growth over the coming years.
Also, the essential force that drives the downstream processing industry is the cumulative demand for biosynthetic products for use in pharmaceutics. Due to their lower risk of side effects, drugs made from naturally occurring sources are currently witnessing increasing demand.
A steady increase in the demand for high-quality pharmaceuticals or recombinant products is expected to drive the downstream processing market at a prolific pace during the forecast period.
Similarly, the rising prevalence of diseases like diabetes, pneumonia, and influenza along with increased awareness of biologics and large molecules is also anticipated to boost demand for downstream techniques during the upcoming years.
Advancements in Downstream Processing to Foster Growth Over the Forthcoming Years
Recently, chromatography adapted to the pharmaceutical industry upon seeing tremendous success in the textile industry, assisting with operations including material preparation and molecular characterization. The downstream processing chromatography industry is experiencing significant advancements with the rise of new therapeutic modalities including monoclonal antibody (mAbs)-based therapeutics.
Pharmaceutical and biopharmaceutical firms are embracing continuous processing, and regulatory bodies support real-time monitoring via process analytical technology (PAT) to control the downstream process. The growth of chromatography systems will also be impacted by the transition from larger, single-product facilities to smaller, multiproduct facilities.
Biopharmaceutical manufacturers are highly focused on effective process control in automation in manufacturing. The pinnacle of intelligence-in-manufacturing, addressed by industry-focused R & D initiatives, is continuously developing through centralized/distributed hardware/software automation systems.
Additionally, the concept of a digital twin for enabling control is shown for a small-scale end-to-end monoclonal antibody production platform. Automation in the manufacturing sector would offer significant opportunities to overcome many constraints to commercial success.
Developers of biotherapeutics must consider large-scale production from the commencement of process development and should incorporate automation techniques. Thus, such advancement will create lucrative opportunities in the downstream processing market.
Principal Consultant
The cost of separation and purification often makes up more than half of the overall process cost. In order to build a cost-effective bioprocess, the downstream process is carefully examined.
Numerous separation and purification procedures have been combined to achieve the requisite degree of purity, which has increased the cost of the downstream process. Even though the efficiency of each stage is satisfactory, the system's extensive steps result in an increase in equipment costs as well as a reduction in the process' overall separation efficiency.
The monitoring and control of bioprocesses, such as downstream processing, have become more complex as a result of production process advancements, particularly in the biopharmaceutical and nutraceutical industries, and the limitations of some modern and some classical control system techniques are now becoming evident.
The above-mentioned factors pose a restrictive impact on the downstream processing industry and call for prompt attention toward optimization techniques for a smooth process flow.
Increasing Demand for Biopharmaceuticals Fuelling the Sales in the USA
In 2021, the USA held a maximum share of about 90.4% in the North American downstream processing market and it is projected to display a growth rate of 10.5% CAGR during the forecast period (2022 to 2032).
Growth in the USA downstream processing market is driven by rising production and consumption of biopharmaceuticals, favourable government support, the surge in chronic and infectious diseases, and the strong presence of leading end-use industries.
The manufacturers based in the USA are focused on expanding their manufacturing facility to broaden their product portfolio and proposed new avenues for research, and would thus propel the growth of the overall downstream processing industry in this region throughout the forecast period.
For instance, in January 2021, Pall Corporation made significant investments in its global production capacity to meet industry demands driven by six existing manufacturing facilities as well as a new manufacturing facility in the USA
Rising Healthcare Spending Generating Demand in Germany's Downstream Processing Market
Germany held approximately 28.1% market share in the global downstream processing market in 2021 and it is projected to expand at a CAGR of 10.9% during the forecast period.
Rising healthcare spending, government funding for developing bioprocess technology, and rapidly expanding healthcare infrastructure are some of the key factors driving demand for downstream processing products in Germany’s market.
Additionally, the nation has seen significant strategic partnerships with pharmaceutical companies that are heavily investing in the research and development of vaccines and biopharmaceuticals. This will further accelerate the growth of the downstream processing market in Germany during the assessment period.
The surge in the Number of Pharmaceutical Companies in India Driving Growth
India accounted for a market value share of around 52.9% in the South Asia downstream processing market in 2021 and it is poised to exhibit strong growth during the next ten years.
Growth in the Indian downstream processing market is driven by rising production and export of biopharmaceuticals, the large presence of pharmaceutical companies, and increasing healthcare spending due to a surge in chronic and infectious diseases.
Improved product portfolio with process development and modeling of flow during bioprocess, through acquisition and merger activities, has deemed the production of bulk compounds as time-efficient, cost-effective, and with improved quality, even with large quantization of cultures. This has proposed new avenues for research, and would thus propel the growth of the overall bioprocess technology industry throughout the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand Remains High for Chromatography Columns and Resins
Based on product, the chromatography columns and resins segment dominated the global downstream processing market with a share of around 37.9% in 2021 and it is likely to grow at a robust pace during the forecast period. This can be attributed to the increasing usage of chromatography columns and resins during downstream processing.
Chromatography columns are being increasingly used for the separation of chemical compounds or pharmaceutical compounds while chromatography resins are used to capture and polish mAbs, vaccines, antibody fragments, and other biomolecules.
The constant technological advancement in chromatography, which is considered a dynamic invention in the field of biopharmaceuticals, is predicted to experience positive progress during the forecast timeframe. This in turn will result in the high adoption of products like chromatography columns and resins.
However, the single-use products segment is anticipated to increase at the fastest rate during the coming years.
Purification Remains the Most Widely Used Downstream Processing Technique
The purification segment held a revenue share of around 43.5% in the global downstream processing market in 2021 and it is expected to experience an impressive growth rate of 13.5% during the forecast period. This can be attributed to the rising adoption of purification techniques for getting pure and quality products.
Purification is a key stage technique in downstream processing as it plays a significant role in enhancing the quality of the product and maintaining the purity of the product.
However, the separation segment is anticipated to grow at the fastest rate during the coming years due to the rising adoption of separating various pharmaceutical compounds across various end-use sectors.
Vaccine Production Will Remain the Most Lucrative Application
The vaccine production segment held the highest market share of 30.1% in 2021 and it is expected to grow at a CAGR of 14.5% during the projected period. The growth of this segment is attributed to the development of low-cost and high-quality products like vaccines using downstream purification technologies.
Similarly, the rising incidence of various chronic and infectious diseases and the growing need for improving the immune system of people will indirectly favour the growth of the vaccine production segment during the next ten years.
Most of the Sales to Remain Concentrate on Biopharmaceutical Companies
As per FMI, the biopharmaceutical companies segment held a market share of around 44.0% in 2021 and it is expected to grow at a CAGR of 8.6% during the forecast period. This can be attributed to the rising usage of downstream processing products like chromatography columns & resins, membrane adsorbers, consumables, and single-use products across biopharmaceutical companies.
Biopharmaceutical companies have gained significant traction with expansive strategies to enhance offerings associated with therapeutic and biological use. They are constantly making efforts to improve their productivity by using novel techniques like downstream processing.
Leading players in the downstream processing market are focusing on the development and launch of next-generation downstream processing products. Apart from that, they are concentrating on the expansion of their manufacturing capabilities with high flexibility and rapid operations.
A few of these strategies undertaken by the market players in the downstream processing market are:
| Attribute | Details |
|---|---|
| Estimated Market Size (2022) | USD 24.9 Billion |
| Projected Market Size (2032) | USD 72.3 Billion |
| Anticipated Growth Rate (2022 to 2032) | 11.3% |
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2012 to 2021 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, Israel, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Product, Technique, Application, End User, and Region |
| Key Companies Profiled | Thermo Fisher Scientific Inc.; GE Healthcare; Sartorius Stedim Biotech S.A.; Merck Millipore; Danaher Corporation; 3M Company; Boehringer Ingelheim; Lonza Group AG; Eppendorf AG; Finesse Solutions, Inc.; Bio-Rad Laboratories; Agilent technologies; Solida Biotech GmBH; Waters Corporation; Applikon BioTechnique/Getinge AB |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The global downstream processing market is expected to reach USD 24.9 Billion in 2022.
The downstream processing market is expected to reach USD 72.3 Billion by the end of 2032, with overall sales likely to grow at 11.3% CAGR throughout the forecast period.
The rising adoption of single-use (disposable) bioprocessing technology, reduction in operating costs due to continuous bioprocessing, an increase in the use of next-generation computing technology in biotech, and surge in the use of biosimilars are the key trends shaping the downstream processing industry.
The USA, Germany, China, Japan, and India are the top five countries driving demand for downstream processing products.
North American held a market share of around 33.6% in the global downstream processing market in 2021.
The MEA downstream processing market is expected to register a CAGR of 11.2% during the forecast period.
The downstream processing market in Japan is expected to grow at a CAGR of 18.4% during the forecast period.
From 2012 to 2021, the global downstream processing market expanded at 5.8% CAGR.
The downstream processing market in India is likely to grow at a CAGR of 18.6% during the forecast period.
Thermo Fisher Scientific Inc., Danaher Corporation (Pall Biotech and Cytiva), Merck KGaA are the key players in the downstream processing market.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 7. Global Market Demand (in Value or Size in USD Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Product 8.1. Chromatography Columns and Resins 8.2. Membrane Adsorbers 8.3. Single-use Products 8.4. Consumables and Accessories 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Technique 9.1. Separation 9.2. Concentration 9.3. Purification 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Application 10.1. Monoclonal Antibody Production 10.2. Vaccine Production 10.3. Insulin Production 10.4. Immunoglobulin Production 10.5. Erythropoietin Production 10.6. Other Applications 11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User 11.1. Biopharmaceutical Companies 11.2. CDMO/Contract Research Organization 11.3. Research/Academic Institutes 12. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. East Asia 12.5. South Asia 12.6. Oceania 12.7. Middle East and Africa (MEA) 13. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 17. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 18. Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032 19. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032 20. Market Structure Analysis 21. Competition Analysis 21.1. Thermo Fisher Scientific Inc. 21.2. GE Healthcare 21.3. Sartorius Stedim Biotech S.A. 21.4. Merck Millipore 21.5. Danaher Corporation 21.6. 3M Company 21.7. Boehringer Ingelheim 21.8. Lonza Group AG 21.9. Eppendorf AG 21.10. Finesse Solutions, Inc. 21.11. Bio-Rad Laboratories 21.12. Agilent Technologies 21.13. Solida Biotech GmbH 21.14. Waters Corporation 21.15. Applikon BioTechnique/Getinge AB 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Downstream Processing Market
